Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Valneva (06/01/2022)

09.01.2022

Valneva: Valneva SE, a specialty vaccine company, today confirms the previously communicated timelines of its clinical trials and regulatory submissions for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. As announced in December 2021, the Company commenced rolling submissions for initial approval of VLA2001 with the European Medicines Agency, the UK MHRA and the Bahraini NHRA, and is continuing to work closely with those authorities to complete their review process following its positive Phase 3 trial results[. Valneva continues to expect potential regulatory approvals in the first quarter of 2022. The Company also announced positive homologous booster results at the end of December 2021. The data showed an excellent immune response after a third dose of VLA2001 administered seven to eight months after the second dose of primary vaccination. Valneva is also evaluating the sera from the boosted participants for cross-neutralization against Variants of Concern, including Omicron. In parallel, the Company is preparing to launch a dedicated heterologous booster trial, which will evaluate a VLA2001 booster shot provided at least six months after primary vaccination with licensed COVID-19 vaccines or following natural COVID-19 infection. VLA2001 is also being evaluated in elderly and adolescent volunteers. The Company expects to report topline data for the elderly trial in the coming weeks.
Valneva: weekly performance: -28.33%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (06/01/2022)


Partners









latest 21st Austria

21st Austria weekly - Valneva (06/01/2022)


09.01.2022, 1547 Zeichen



Valneva: Valneva SE, a specialty vaccine company, today confirms the previously communicated timelines of its clinical trials and regulatory submissions for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. As announced in December 2021, the Company commenced rolling submissions for initial approval of VLA2001 with the European Medicines Agency, the UK MHRA and the Bahraini NHRA, and is continuing to work closely with those authorities to complete their review process following its positive Phase 3 trial results[. Valneva continues to expect potential regulatory approvals in the first quarter of 2022. The Company also announced positive homologous booster results at the end of December 2021. The data showed an excellent immune response after a third dose of VLA2001 administered seven to eight months after the second dose of primary vaccination. Valneva is also evaluating the sera from the boosted participants for cross-neutralization against Variants of Concern, including Omicron. In parallel, the Company is preparing to launch a dedicated heterologous booster trial, which will evaluate a VLA2001 booster shot provided at least six months after primary vaccination with licensed COVID-19 vaccines or following natural COVID-19 infection. VLA2001 is also being evaluated in elderly and adolescent volunteers. The Company expects to report topline data for the elderly trial in the coming weeks.
Valneva: weekly performance: -28.33%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (06/01/2022)



BSN Podcasts
Der Podcast für junge Anleger jeden Alters

Wiener Börse Plausch S2/35: Verbund wird vom Passagier zum Piloten und macht ein Webinar, dazu ein Immo-Update




 

Bildnachweis

Aktien auf dem Radar:SBO, VIG, Strabag, Kapsch TrafficCom, Flughafen Wien, Palfinger, Erste Group, DO&CO, Andritz, Uniqa, FACC, Mayr-Melnhof, CA Immo, Cleen Energy, EVN, Frequentis, Verbund, Wolford, Wolftank-Adisa, Wiener Privatbank, Oberbank AG Stamm, BKS Bank Stamm, Semperit, Immofinanz, S Immo.


Random Partner

Novomatic
Der Novomatic AG-Konzern ist als Produzent und Betreiber einer der größten Gaming-Technologiekonzerne der Welt und beschäftigt mehr als 21.000 Mitarbeiter. Der Konzern verfügt über Standorte in mehr als 45 Ländern und exportiert innovatives Glücksspielequipment, Systemlösungen, Lotteriesystemlösungen und Dienstleistungen in mehr als 90 Staaten.

>> Besuchen Sie 61 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten